Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPAR gamma and RXR alpha Article

Hui, Hui, Chen, Yan, Yang, Hao et al. (2014). Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPAR gamma and RXR alpha . INTERNATIONAL JOURNAL OF CANCER, 134(5), 1195-1206. 10.1002/ijc.28435

Open Access International Collaboration

cited authors

  • Hui, Hui; Chen, Yan; Yang, Hao; Zhao, Kai; Wang, Qian; Zhao, Li; Wang, Xiaotang; Li, Zhiyu; Lu, Na; Guo, Qinglong

sustainable development goals

authors

publication date

  • March 1, 2014

webpage

published in

keywords

  • ACTIVATED RECEPTOR-GAMMA
  • ACUTE PROMYELOCYTIC LEUKEMIA
  • AML
  • ARSENIC TRIOXIDE
  • C/EBP-BETA
  • CANCER CELLS
  • EX-VIVO
  • GRANULOCYTIC DIFFERENTIATION
  • HUMAN MONOCYTES
  • Life Sciences & Biomedicine
  • Oncology
  • PPAR gamma
  • RETINOIC ACID
  • RXR alpha
  • STIMULATING FACTOR
  • Science & Technology
  • differentiation
  • oroxylin A

Digital Object Identifier (DOI)

publisher

  • WILEY

start page

  • 1195

end page

  • 1206

volume

  • 134

issue

  • 5